Evidence map›Paper›PMID 32181993›Full record

ReviewThoracic cancer2020

Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.

Kazuaki Harada, Makoto Ogasawara, Akane Shido, Akimitsu Meno, Soichiro Oda, Shota Yoshida, Sonoe Yoshida, Ayumu Yoshikawa, Ko Ebata, Satoshi Abiko and 4 more

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Checkpoint-inhibitor induced Polyserositis with Edema.Cancer immunology, immunotherapy : CII · 2022
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Kazuaki HaradaDepartment of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan.ORCID 0000-0001-9577-1884
Makoto OgasawaraDepartment of Cardiovascular Medicine, Kushiro Kojinkai Kinen Hospital, Kushiro, Japan.
Akane ShidoDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Akimitsu MenoDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Soichiro OdaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Shota YoshidaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Sonoe YoshidaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Ayumu YoshikawaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Ko EbataDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Satoshi AbikoDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Naoki KawagishiDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Itsuki SanoDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Hisashi OdaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Takuto MiyagishimaDepartment of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Kushiro Rosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several studies have demonstrated increased pericardial effusion during anti-PD-1 immunotherapy, and treatment in patients who have developed pericardial tamponade is controversial. In this study, we describe a 63-year-old woman with stage IVA lung adenocarcinoma given pembrolizumab as a first-line therapy. After four cycles of pembrolizumab treatment, the patient suddenly developed a pericardial tamponade. Although pericardial effusion was increased, her tumor lesions were reduced. After an emergency pericardiocentesis, she continued the pembrolizumab therapy without recurrent pericardial effusions for three months until the primary tumor and lymph node metastasis progressed. Nine months after the pericardiocentesis, the patient died of progressive lung cancer, but pericardial effusion did not recur throughout the treatment course. This case study suggests that pembrolizumab therapy can be continued with a strict follow-up in some patients with pembrolizumab-induced pericardial tamponade. KEY POINTS: • Significant findings of the study Our patient developed pericardial tamponade during pembrolizumab treatment but continued pembrolizumab treatment after emergency pericardiocentesis without recurrent pericardial effusions. • What this study adds Pembrolizumab treatments may be resumed with a strict follow-up in some patients with treatment-related pericardial tamponade.

Indexed as

Adenocarcinoma of LungAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCardiac TamponadeFemaleHumansLung NeoplasmsMiddle AgedNeoplasm Recurrence, LocalPrognosisAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalpembrolizumabImmune checkpoint inhibitorpembrolizumabpericardial effusionpericardial tamponade

Identifiers

PMID32181993
PMCPMC7180565
OpenAlexW3010785746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.